open access

Vol 29, No 4 (2022)
Study Protocol
Submitted: 2021-12-16
Accepted: 2022-03-16
Published online: 2022-04-19
Get Citation

Trimethylamine-N-oxide (TMAO) versus echocardiographic, biochemical and histopathological indices of heart failure in patients with severe aortic stenosis: Rationale and design of the prospective, observational TASTE study

Aleksandra Gąsecka12, Łukasz Rzepa1, Michał Konwerski1, Magdalena Zawadzka1, Karol Wysocki1, Monika Budnik1, Paweł Czub3, Radosław Wilimski3, Mateusz Wondołkowski3, Joanna Wilczyńska-Burlikowska1, Piotr Scisło1, Marek Konop4, Zenon Huczek1, Janusz Kochman1, Janusz Kochanowski1, Grzegorz Opolski1, Krzysztof J. Filipiak5, Marcin Ufnal4, Agnieszka Kapłon-Cieślicka1
DOI: 10.5603/CJ.a2022.0023
Pubmed: 35470417
Cardiol J 2022;29(4):691-697.
  1. 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
  2. Laboratory of Experimental Clinical Chemistry, Academic Medical Center, Amsterdam University Medical Centers, The Netherlands
  3. Department of Cardiac Surgery, Medical University of Warsaw, Poland
  4. Department of Experimental Physiology and Pathophysiology, Laboratory of Center for Preclinical Research, Medical University of Warsaw, Poland
  5. Department of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland

open access

Vol 29, No 4 (2022)
Study protocol — Clinical cardiology
Submitted: 2021-12-16
Accepted: 2022-03-16
Published online: 2022-04-19


Not available


Not available
Get Citation


aortic stenosis, trimethylamine N-oxide, trimethylamine, metalloproteinase, galectin-3, indoxyl sulphate

About this article

Trimethylamine-N-oxide (TMAO) versus echocardiographic, biochemical and histopathological indices of heart failure in patients with severe aortic stenosis: Rationale and design of the prospective, observational TASTE study


Cardiology Journal


Vol 29, No 4 (2022)

Article type

Study Protocol



Published online


Page views


Article views/downloads






Bibliographic record

Cardiol J 2022;29(4):691-697.


aortic stenosis
trimethylamine N-oxide
indoxyl sulphate


Aleksandra Gąsecka
Łukasz Rzepa
Michał Konwerski
Magdalena Zawadzka
Karol Wysocki
Monika Budnik
Paweł Czub
Radosław Wilimski
Mateusz Wondołkowski
Joanna Wilczyńska-Burlikowska
Piotr Scisło
Marek Konop
Zenon Huczek
Janusz Kochman
Janusz Kochanowski
Grzegorz Opolski
Krzysztof J. Filipiak
Marcin Ufnal
Agnieszka Kapłon-Cieślicka

References (30)
  1. Ufnal M, Zadlo A, Ostaszewski R. TMAO: A small molecule of great expectations. Nutrition. 2015; 31(11-12): 1317–1323.
  2. Lever M, George PM, Slow S, et al. Betaine and trimethylamine-n-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS One. 2014; 9(12): e114969.
  3. Jaworska K, Bielinska K, Gawrys-Kopczynska M, et al. TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome. Cardiovasc Res. 2019; 115(14): 1948–1949.
  4. Jaworska K, Konop M, Hutsch T, et al. Trimethylamine but not trimethylamine oxide increases with age in rat plasma and affects smooth muscle cells viability. J Gerontol A Biol Sci Med Sci. 2020; 75(7): 1276–1283.
  5. Gawrys-Kopczynska M, Konop M, Maksymiuk K, et al. TMAO, a seafood-derived molecule, produces diuresis and reduces mortality in heart failure rats. Elife. 2020; 9.
  6. Huc T, Drapala A, Gawrys M, et al. Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats. Am J Physiol Heart Circ Physiol. 2018; 315(6): H1805–H1820.
  7. Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013; 62(11): 1002–1012.
  8. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003; 24(13): 1231–1243.
  9. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012; 60(19): 1854–1863.
  10. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999; 341(3): 142–147.
  11. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
  12. Joseph J, Naqvi SY, Giri J, et al. Aortic stenosis: pathophysiology, diagnosis, and therapy. Am J Med. 2017; 130(3): 253–263.
  13. Treibel TA, Kozor R, Schofield R, et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol. 2018; 71(8): 860–871.
  14. Kayama S, Aratake S, Sawamura S, et al. Medium and long-term prognosis of transcatheter aortic valve implantation from the perspective of left ventricular diastolic function. Cardiol J. 2019; 26(1): 29–35.
  15. Bjørnstad JL, Neverdal NO, Vengen OA, et al. Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during one year of left ventricular reverse remodelling in patients operated for severe aortic stenosis. Eur J Heart Fail. 2008; 10(12): 1201–1207.
  16. Kupari M, Laine M, Turto H, et al. Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis. J Heart Valve Dis. 2013; 22(2): 166–176.
  17. Zhong X, Qian X, Chen G, et al. The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol. 2019; 46(3): 197–203.
  18. Fu Q, Cao L, Li H, et al. Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies. Chin Med J (Engl). 2014; 127(16): 3011–3018.
  19. Lekawanvijit S, Kompa AR, Manabe M, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One. 2012; 7(7): e41281.
  20. Organ CL, Otsuka H, Bhushan S, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016; 9(1): e002314.
  21. Ufnal M, Jazwiec R, Dadlez M, et al. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol. 2014; 30(12): 1700–1705.
  22. Jaworska K, Hering D, Mosieniak G, et al. TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. Toxins (Basel). 2019; 11(9).
  23. Jaworska K, Huc T, Samborowska E, et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One. 2017; 12(12): e0189310.
  24. Yancey PH, Siebenaller JF. Co-evolution of proteins and solutions: protein adaptation versus cytoprotective micromolecules and their roles in marine organisms. J Exp Biol. 2015; 218(Pt 12): 1880–1896.
  25. Burg MB, Ferraris JD. Intracellular organic osmolytes: function and regulation. J Biol Chem. 2008; 283(12): 7309–7313.
  26. Konopelski P, Ufnal M. Indoles: gut bacteria metabolites of tryptophan with pharmacotherapeutic potential. Curr Drug Metab. 2018; 19(10): 883–890.
  27. Lekawanvijit S, Krum H. Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins. J Physiol. 2014; 592(18): 3969–3983.
  28. Reuillard A, Garrouste C, Pereira B, et al. Evolution of chronic kidney disease after surgical aortic valve replacement or transcatheter aortic valve implantation. Arch Cardiovasc Dis. 2019; 112(3): 162–170.
  29. Vavilis G, Bäck M, Occhino G, et al. Kidney dysfunction and the risk of developing aortic stenosis. J Am Coll Cardiol. 2019; 73(3): 305–314.
  30. Winther SA, Øllgaard JC, Tofte N, et al. Utility of plasma concentration of trimethylamine n-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes. Diabetes Care. 2019; 42(8): 1512–1520.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: